Targeting the unstable atherosclerotic plaque : diagnostic and therapeutic implications Segers, F.M.E.

Hele tekst

(1)Targeting the unstable atherosclerotic plaque : diagnostic and therapeutic implications Segers, F.M.E.. Citation Segers, F. M. E. (2010, May 6). Targeting the unstable atherosclerotic plaque : diagnostic and therapeutic implications. Retrieved from https://hdl.handle.net/1887/15348 Version:. Corrected Publisher’s Version. License:. Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded from:. https://hdl.handle.net/1887/15348. Note: To cite this publication please use the final published version (if applicable)..

(2) Chapter. 5.

(3) .

(4) . Imaging Signal in Atherosclerotic Lesions. Filip M.E. Segers1 1 2 ! " # $2, % #& ' (& !) % *, Menno P. de % 5, Robert E. Poelmann2 +"" -1, / - "!" 1,6. 1. 0 $

(5) ) !3 $ 0 ) ! 4 ( !. 7 2. 0

(6) $ ( /' (( ! 4 ( ! 7 &. 8) #) ' )()' 9 *. 0

(7) $ ( ! 4 ( ! 7 5. 0

(8) $ ) # ) ) . 4 ( 7 6. 0

(9) $ : ( ) ) 4 (. 7 . ;)

(10)

(11)

(12) <.

(13) Part II: Diagnostic and Therapeutic Implications. ABSTRACT. Background $ ) $

(14) >. $ ? ( -

(15) 8) .

(16) $

(17) ; < ( @

(18) . '(

(19) - $$ (" Methods and Results @ ' 4:B 8)

(20)

(21)

(22)

(23) . ;C"&GH 93! C"CHJ ::H3!<" ) ) .

(24) )' 4:B > ( . )

(25) - 4:B K) $ 8) '

(26) .

(27)

(28) ( : N " ' ( .

(29) " 4

(30) K

(31) /3 4:B

(32) (.

(33) ( &"O $ ;

(34) QC"CH< .

(35) 8) ))

(36) 4:B" % '( . ( $ !0! 3 )-( @

(37) $ ). ) )-( >( >

(38) . ;"G$U

(39) QC"CC&< . @

(40) $ ) * $ K $ 4:B" Conclusions ( ) ) .

(41) >

(42)

(43) (

(44)

(45)

(46) $ . $ ? (

(47) 8) $ ". 108.

(48)

(49) ) . INTRODUCTION. 109. Chapter 5. Despite ) ) $

(50) $ ) . ) ( ;< )

(51) (.

(52)

(53)

(54) $ $ ') -

(55) > (. $(

(56) 8) - $ ' (. (

(57) " 7 ) . ; < ( ' ( - $ )' $. plaque composition and an accurate discrimination between stable and unstable " ) ( ( $ )

(58)

(59) . '

(60) ( ) . $ ) ) 1" @

(61) $ ) . 9 )@ HC ) )

(62)

(63) ' @

(64) . ;4:B<" 4:B ( '

(65)

(66) $ $ &, multiple sclerosis lesions * O ? ( $ ) ( 6 and atherosclerotic plaquesG J" 4:B

(67) ( ( $ . '

(68) (

(69) ( 9 '(

(70) . )

(71) ( $ $ ) )

(72) (

(73) . macrophages and peripheral tissue macrophages10, 11" 7

(74) 8). )

(75) - $>

(76) '( ) $> ( $ K .

(77) " 4:B

(78) (

(79) $. )

(80) G ( 12 '$

(81) " @ .

(82) ( @)( ) ( ( . '(N

(83)

(84) (

(85) . ' ;'< >( $ $ J* (1. % ) $

(86) )

(87)

(88) ' $$. ( '

(89) '( ( @ $$ )H&. -

(90) $ ( > . $$

(91) $ )'8) . arterial intimaH*. Plaque

(92) ( @

(93)

(94) . ; < ' )

(95) ( ) . developmentHOHJ.

(96) )

(97) - $ >

(98)

(99) . ) $ $

(100)

(101) ? (

(102) (

(103) $

(104) 19. Abundant scavenger receptor @

(105) $)

(106) > $ ) ). ') ( 20, 21. Relevant to vulnerable plaque detection ') @

(107)

(108) ? (. $ " ' $>

(109) ( $ ') )' 8)>

(110) . $

(111) 8) ) ) (

(112)

(113) " Due to the

(114) @ ) $ - ) )'

(115) . $

(116) $ ' ))$)" % . ( > HO

(117)

(118) ::H '(

(119)

(120) ( ' ( .

(121) Part II: Diagnostic and Therapeutic Implications. shows high in vitro and in vivo $> (

(122) > ( $ ' ) ) . macrophage scavenger receptor class A22. ) ) )( '

(123)

(124) $ . 4:B

(125) $)

(126) >

(127)

(128) " 4:B.

(129) ( ' $ $ . macrophage uptake. The latter resulted in enhanced MRI signal in macrophages in vitro and in vivo in atherosclerotic plaques.. MATERIALS AND METHODS Cell culture. %X*"G )

(130) ) Y:H ( ;$ $ . #) ' # )

(131) < &GZ )>

(132) ;O[ B2< . 0)'N > /N ) ;0/< : HX*C )

(133) (. )

(134)

(135) HC[ 9 ) ;9< ;Y &C OXZ<. 3! !) HCC 43 : HCC\3

(136) ( ; $ . : ]' # (<" Y:H ( $$

(137) . '( )'

(138) ' H( H& ;: HCC. ""< ; ^K 7 <" 9) ; ^K . 7 < ) ' $ " Animals. -

(139) $

(140) 0) . guidelines. ApoE3 ;H( < $ !0! 3 ; JH -< . ' $ ' $ (" H3 $ +-. !' ( ; Y ' 4< ) . @

(141) > '- ) ' $ 0 " . % 4 ( 7 " . -

(142) ) ' ( " 0

(143) ad libitum )) @

(144) " Bone Marrow Transplantation and induction of hypercholesterolemia. Female LDLr_3_ mice ( '( $ ` #( ;C"H` #(3. CC -f * < '( ) @ O ] source ;jx!B7

(145) 0 -< 8)

(146)

(147) X )) > ". '( ?) $) ' $ .

(148)

(149) ')$$ ;:<" )

(150)

(151)

(152) '(.

(153) ) &C\ ( )"

(154) . C"O@HCG bone marrow '( ) K " $ . ( $ X - ( . HO[ ;3< $ C"O[ ;3< ;0 %U ' % . 7 < $ HHJ -" 0 - )

(155)

(156) ' ;J&. 3!

(157) ?@ XG 3!

(158) ((@ )$ < X"O 3! ) " ). ) @

(159) '

(160) . '( ' ( & - $ $

(161) . 110.

(162)

(163) ) . " 8) >

(164)

(165) ( ) . (

(166) ) ; 0 # (<" :

(167) . ) ; # (< ) " MRI. @

(168)

(169) $ `"* ;*CC Y< J` ' . $ )- f7/ ; )-

(170) #'Y / . # (< 8)

(171)

(172) : f O"C $ . ( "O ( ;H 3<" . 3 ' $ 8)( $ &"C . ; )-

(173) #'Y / # (<". Image Analysis. 9

(174) ' ' & * K. $ $ )( ;+< . " ( ) + $ " $ ; B< . ) ;<" B ) ). $ ) ;)<" 9) B

(175) ) . ) ; <". 111. Chapter 5. In vivo MRI analysis (

(176) $ ' '. ;

(177) /3 and bone marrow transplanted LDLr3 <" ( . )

(178) K ;OCy. 93-<" * $ 4:B K ?) ;[. <" 0) @

(179) ))( ) . with a balloon pressure sensor using a respiration cushion under the mouse chest /#3

(180) ( ) ; ) " ( - 7j<. ?) K) -

(181)

(182) ' . OC JC

(183) 3" $ @ 0 9!Y ) . @

(184) $ $ . " $

(185) ) $ ) z Y

(186) 9

(187) ) H"CCC U ?

(188) ;9< HCU

(189) ; < H*"G U . ;/< H"J U

(190) *C -YU

(191) &C[U > $ ;9Bf<. H"J{H"J U @ HJ{HJU

(192) ) C"H*H U - C"*. U )' $

(193) X*U 8)

(194)

(195) @ ( . > 9!Y 8) ; # < ) $.

(196) 7/ $

(197) z Y

(198) 9

(199) ) H"CCC U 9 HO|U HO"G U / "`X U

(200) . *C -YU

(201) &C[U

(202) X*U HC $ U 9Bf. "OX{"OX U @ HJ{HJU

(203) ) C"CC U -. C"O U )' $

(204) *CCU 8)

(205)

(206) @ ( H* .

(207) Part II: Diagnostic and Therapeutic Implications. Histology and Morphometry ( ;HC\<

(208)

(209) $

(210)

(211) . B B" ) $ JHC ) . B B ;B B< " !

(212) . $ )

(213)

(214) > '(. ; #' ) HzOCU B@$ 4}<" (. '( #: ;HzHCCU !) B< ( )' . 7 ) ) _ O * &( :

(215) ;7:< ;0-. # )

(216) 0 -< )"

(217) ) '( . : N "

(218) ( B B

(219) $ . ) ! ~ ( $ !0 /

(220) ;!. ( ' 4}<" : N

(221) ) )(. and in a blinded manner. Quantitative analysis of iron dosages in plasma and organs.

(222) '(

(223) ) )

(224) ". 4

(225) > ) in situ :

(226) $) . $ " B $ JC|. ) $) (" $ ) ) ) . '( ) ( )

(227)

(228)

(229)

(230) ( ;:/< ;B

(231) . &&CC ! : - / ) ')$ 9 <. 112.

(232)

(233) ) . RESULTS Increased uptake of scavenger receptor targeted USPIO by macrophages in vitro - $ )

(234) -

(235) $ 4:B in vitro and in vivo9 have ' )'K $ ) ) )" Y ) 4:B. ) '

(236) 8)

(237) > '( K) $ (

(238)

(239) . $

(240)

(241) )( ' ( @

(242) '(.

(243) ? ( $

(244) 8)&. Quantitative atomic absorption

(245)

(246) ( ( >. )

(247) - %X*"G )' ;4:B<. ) 4:B ;&CCy 93< ;HG` HO JCO HHH. 93

(248)

(249) C"CCH >) O"H<" )

(250) - ) ). Y:H

(251)

(252) '( > ) )

(253) -. $ 4:B ;XCC &O< 4:B ;&*& *J 93

(254)

(255) QC"CH<". 4:B )

(256) - ) ' '- '(

(257) )' $ $) . ' ' $ 3* ;>) O"H<". **. 2.0. ***. 1.5. **. 1.0 0.5 0.0. USPIO. T-USPIO. p= 0.01. p= 0.01. 0.7 0.6 0.5 0.4. **. 0.3. ns. 0.2. THP-1. *. ***. 75. 70. 65. 0.1 0.0. Control. D. USPIO. T-USPIO. 60. Control. USPIO. T-USPIO. Chapter 5. Control. C. THP-1. T2 relaxation (msec). B. RAW264.7. Iron uptake (ng Fe/g). Iron uptake (mg Fe/g). A. E. USPIO. T-USPIO. Figure 5.1

(258)

(259)

(260)

(261)

(262)

(263)

(264)

(265)

(266)

(267) . !"#####$ $ in vitro macrophage cell cultures. Cells without contrast agents served as control. (A) RAW264.7 macrophages were incubated with T-USPIO

(268)

(269) &'*+ #",

(270) , / $ $01 1351$ , $01,

(271) #

(272) $, $##$

(273) # ,

(274) #,

(275) 1 89+ : ;< ,

(276) *# "$ * "*$

(277) "$ *

(278) 5, $ *$5$

(279) ,

(280) $ +="$ ,5

(281) &'*"$ * +

(282) "# $ 51895#$

(283) 1#$#

(284) ,1# # ,

(285) ,

(286)

(287) $ ,

(288) +& > $

(289) $#

(290) *#, #"#

(291) 1351?@+

(292) "#B, 51#$ loss in T2"$* ?@ 1#$#

(293) , #+;<$ ,5 "$ *D 9" # $

(294) $

(295) "$ *E## $ $

(296) 0$#$3$ ,$

(297)

(298) #$ $

(299) +D #*

(300) " # F 9?+*p<0.05, **p<0.01 and ***p<0.001). 113.

(301) Part II: Diagnostic and Therapeutic Implications. 4:B )

(302) - '( Y:H

(303) '(

(304) . K) '( 2 @ )' 4:B ;XO"*. C"X U

(305) QC"CH<

(306) )

(307) ;G"O H"*<. ;9) O"H<" )' $) ') @ . $ 4:B ') @ $ 4:B )'

(308) .

(309) '

(310) )( ) $

(311) 4:B. )

(312) -" $ @ $ $)

(313) ' . $

(314) " -

(315) : N $ Y:H

(316) . > ')

(317) $ )

(318) . 4:B )'

(319) ;>) O"H0/< " ) ( . 4:B

(320) > ( .

(321) )

(322) - '(

(323) " Increased plasma clearance and increased signal in vivo upon targeted delivery of USPIO in ApoE-/- mice. 4. Iron Dosage (P mol Fe/g tissue). Iron Dosage (P mol Fe/g tissue). @

(324)

(325) 8) )) $ . 4:B

(326) in vivo H(

(327) /3 ;7QH*< '. " )' $ ). K 4:B ;OCy 93- 7QX< )

(328) . )

(329) ;OCy 93- 7QX<" . ) ) ) " } ( $

(330) . '( :/

(331)

(332) $ 4:B ;H3 Q H"G<

(333) ) ;H3 Q "Ù :C"CO<" 9. ' ' $

(334) * $ . ;>) O"<". *. 3. * 2. *. 1. 0. 4. 8. 12 Time (h). 16. 20. 24. 12. 9. 6. 3. 0. *. Liver. Spleen. Kidneys. Lungs. Figure 5.2

(335)

(336)

(337)

(338) ! 88

(339) 9<1

(340) $,,$0KLM

(341) KLM&=

(342) 51$ 0

(343) #$ N, $

(344) +?

(345) , $ N, $,#0#,

(346)

(347) were used to determine endogenous tissue iron concentrations. Blood samples were collected at 1, 2, '!X!<'* &'*

(348) $

(349) #,$Y,+## #"#5N,

(350) 89

(351) $,5#

(352) $

(353) spectroscopy and iron content in mice treated with T-USPIO (z) and untargeted USPIO ({) was determined (A). At 24h after administration, organs of interest were harvested and analyzed for iron 5189:+*# #

(354) *

(355)

(356) #*

(357) " $ "*$ 5#!"*$. *

(358) #

(359) $ $, $ 5, +Z15# #

(360)

(361) # $##$

(362) ,

(363) #

(364) ,

(365)

(366) $,+D #*

(367) " # F9?+*p<0.05). 114.

(368)

(369) ) . ( $

(370) )

(371) ) . -( $ * $ K )) .

(372) ( 4:B 4:B . ;&&OO &OO 93 )U

(373) C"CO< ) ;HO``. &H& 93<" ' ')

(374) > $ 4:B 4:B . > ( $$ $ $ ) ;9) . O"<" !

(375) ( ; >) O"&< . ( $ ( 3

(376) )) ". @

(377) $$ ' ;>) O"&< . ( 3

(378) * $ ;>) O"& 09<". Y ) $ )

(379) - '( : N > . &"&$ : N

(380) $ 4:B K .

(381) 4:B ;:QC"CH<" B) ) . targeted contrast agents combine accelerated plasma clearance with increased accumulation in advanced atherosclerotic lesions.. A. B. Plaque size (*105 mm2). T-USPIO. USPIO. C 10. ns. 8 6 4 2 0. E 15. USPIO. ns. 10. 5. H. Perl's + cells/plaque (mm2). 0. G. T-USPIO. F. Chapter 5. % MoMa-2 staining. D. USPIO. T-USPIO. p= 0.0116. I 30. 20. 10. 0. USPIO. T-USPIO. Figure 5.3 "!#

(382)

(383)

(384)

(385)

(386)

(387)

(388) atherosclerotic plaques in ApoE!$! 8 8

(389) 9 (1-year old) mice received an intravenous $ N, $

(390)

(391)

(392) &=

(393) KLM

(394) &=

(395) KLM+8 &'*$,"#,$Y, #, $

(396) #"

(397) * *

(398) #,

(399) $,#$

(400)

(401)

(402) $,

(403)

(404) +*##, $

(405) #"#5#/ 1# $

(406) E#Z;!$@8! ?

(407) ?&D+ /#$3 ,

(408) *,

(409) " $ "$ *,

(410) ##$# $ 1#$#+ (I)Perl’s stained sections were analyzed in a blinded manner and Perl’s stained cells were individually #,

(411) # #\E#

(412) #$ $0,# /+D #*

(413) " # F9?+. 115.

(414) Part II: Diagnostic and Therapeutic Implications. T-USPIO show superior accumulation in plaques in a humanized mouse model of atherosclerosis. Plaque Size (*105 μm²). )

(415)

(416) ::H25 had even $> ( $ ) Y:H

(417) $ ) .

(418) ) ::H ( ' 8)( $$ . )

(419) 8)"

(420) $ )

(421) 8) . generated LDLr3

(422) ) @

(423) '( '.

(424) "

(425) >( . " $ (

(426) $ X - ) '(. $" )

(427) $ ). $ ::H ;4:BU OCy 93-<" * . were anesthetized and subjected to in vivo magnetic resonance imaging on a `"*

(428)

(429) )" -

(430)

(431) ) >X G morphometric ( ( $$

(432) 8) ' 3 . ;>) O"*<"

(433) (

(434) 8) ( 3

(435) $ . $$ ;>) O"*09<" In vivo (. $ > ( . @

(436) ;HG"* "&<

(437) 3 ;X"* . C"OU

(438) QC"CC*< ;>) O"O<" (

(439) . ) )

(440) - @

(441) " ) (. )

(442)

(443) ( $ )) .

(444) " ns. 10. 5. % Monocytes/Macrophages. 0. 25 20 15 10 5 0. !$!. ns. 30. -/-. SR-A !$!. hSR-AI ki. Figure 5.4&,&

(445)

(446)

(447) "!#:;"!# < "!# = ;"#< > ?

(448) 8 5

(449)

(450) " # $

(451) ! _D_ chimeras with hematopoietic SR-A 1 5# *@8

(452) 0> ##$

(453) 5, 5#! " *$*,*

(454) #

(455) $

(456) $ , *

(457) #,

(458) $, /

(459) $

(460) +:

(461) *

(462) #,$0#$ $ N, $

(463)

(464) &=

(465) &'* $,"#,$Y,!

(466) #">,$#+1

(467) #, $

(468) # "

(469) * *

(470) #,

(471) $,#$

(472)

(473)

(474) $,

(475)

(476) #5#/ 1# $

(477) $@ 8: ?

(478) ?&D9+/#$3 ,

(479) *,

(480) " $ "$ *,

(481) ##$# $ 1#$#+D #*

(482) " # F9?+. 116.

(483)

(484) ) . A. B. 0. C. CNR. -5. -10. -15. -20. ** SR-A -/-. hSR-A ki. 117. Chapter 5. Figure 5.5 In vivo @

(485) "

(486)

(487)

(488)

(489)

(490) "!# = &,& !$! After bone marrow. # $

(491) ! _D_ ,*$# " *$* ,*

(492) #

(493) $

(494) $ , *

(495) #,

(496) $, / formation. SR-AKL'!15# *@8

(497) 0> ##$ KLM!5, 5#5

(498)

(499) ",$ $ # ,$0#$ $ $# $

(500) "$ * &=

(501) +8 &'* $ N, $

(502) !$," #5N,

(503) $ 0$0

(504) $,#

(505) ,$$ #5#/ 1#,$Y,+

(506) #

(507) K

(508) $#@ $

(509) K@ "# $ 51 ,

(510) ##$# 1#$#

(511) ?@ $# 8:+

(512) ,*

(513) # * $#" 13 K@"# $ +D #*

(514) " # F9?+(**p<0.01).

(515) Part II: Diagnostic and Therapeutic Implications. DISCUSSION 4 )

(516)

(517) @

(518) ;4:B< ( ) $ 28, ? ( )

(519) 7

(520) . lesionsG" B $ K ) (. ' ' ) ' )

(521) )

(522) " . (

(523) > '( ')

(524) $ )-( )

(525) .

(526) (

(527) 8) ' 29"

(528)

(529) (. $ ) '

(530) 8) " . '

(531) ( @

(532) .

(533) 8)

(534) $> ( ( )' ( . compartmentHO &C &H" B) )

(535) ( )$)( > HO.

(536)

(537) ;::H<

(538) > ( $> ( $

(539) 22. Y ' K) $ ::H 4:B

(540) ( . ) ( $ ::H K) 4:B

(541) in vitro and in vivo but also enhanced MRI image contrast in macrophage rich atherosclerotic

(542) 8) ) $ " >

(543)

(544) 4:B ) ( . ::H

(545)

(546) ;O[U C"CHJ ::H3! C"&GH 93!< $ $ . 4:B" B) ) in vitro )

(547) - $ 4:B ) . ;"H$< )

(548) ;H"J $<

(549) ) . )

(550) " ) )

(551) -

(552) ( ') '( $)" ' > - ::H $ ::H. 4:B

(553) $ ( - )

(554) '(

(555)

(556)

(557) ( " ( )

(558) - $ . 4:B '(

(559)

(560) ( ' '( $) -

(561) .

(562) ) )

(563)

(564) 4:B )

(565) -9. (

(566) )) $ 4:B in vitro $>. $ ) 4:B" The in vitro )) $ 4:B > in vivo. In vivo )) $ $ ). administration in aged ApoE3 mice with advanced atherosclerotic lesions. As

(567) )( @

(568) $

(569) .

(570) ; "

(571) ) <" 4:B $ .

(572) (

(573) )

(574) - 4:B" )) . '( '( " ' ') .

(575) > $ 4:B $ 125' ::H22" 4:B . 4:B '

(576) ( $

(577) * ) $ . " ( ) )

(578) - $ . $ ' ( '> $ (". )

(579) > 4:B )) ) ) ). $) " 9) $. 118.

(580)

(581) ) . 119. Chapter 5.

(582) - $ 4:B ( @ (".

(583) ( - $ 4:B

(584) $ . ))

(585) . 4:B" )

(586) - ') ' $$ . ) ( )

(587) - $ .

(588) '( @

(589)

(590) 8)

(591) ". @ @

(592) @ > ). $ !0! 3

(593) @

(594) $ ). " % !0! 3

(595)

(596) > @

(597) . the human macrophage scavenger receptor class AG & )-( >(26. In vivo ( )

(598) - $. 4:B

(599) 8) $ @

(600) ) &&. Again neither plaque size

(601) $$ ' )

(602) ".

(603) '

(604) )' $ ? . $ ) '

(605) 8)"

(606)

(607) . $ ( ? ( -( $$ 29 ')

(608) 8) - $ . complications&*&X" ) ( K

(609)

(610) @ $

(611) 8).

(612) ("

(613) '

(614) . ( $

(615) $ 4:B

(616) 8) ). ( $ 4:B )

(617) - '( ( )'8) . into the atherosclerotic plaque&G" ( $

(618) 8).

(619) '

(620) ( ) #' - .

(621) > ; '(< 3&J" 7@

(622) . ( $ ) '

(623) 8)

(624)

(625) ' $. targeted plaque imaging, including apoptosis&`, necrosis&`, neovascularization, > !0!*C *H @ ) @ :N ' ) # based MR molecular imaging agents*. ) ) )(

(626) >

(627) . ) ) 4:B' . $> (

(628) > ( $ ) ) $

(629) . @

(630)

(631) ) ' .

(632) 8) ) ) )( )$)(

(633) . @'

(634) . )

(635) - '(

(636) ) ".

(637) ' ( ) . $> ( $ $$

(638) )

(639) -. '(

(640) 8)

(641) " ) (

(642) ( . $ ' $

(643) 8) . ) $ " % $ ) . )

(644) >

(645)

(646) )

(647)

(648) $ $ . $

(649) $ ? ( . such as the atherosclerotic plaque and might even allow selective discrimination $ ) '

(650) 8)".

(651) Part II: Diagnostic and Therapeutic Implications. REFERENCES. 120. H". ' : + : " @ ( ( $. " 0 ) 0 " CCXUOJzH*GHHOC*". ". j : % B) /} $ % )- 0 7) ' : . } 9 0/ 4: )' + 9 Y / :

(652) ( ". /) $ - '( $ )@ HC z.

(653) $ ( $>( )(" (" CC&UJzGGGGJJ". &". Y # + Y :9 0 % ' ' } Y . + % " 7 $ ( ) (

(654) .

(655) " 7 / + " CC&U&*Jz*`H*``". *". ) Y : ) 0 ) " ' $ ? . ) )

(656) //" " CC&UOCz&C`&H*". O". ) Y : 9 ) 0 ) " : ' ( $ 9jGC. $>( @

(657) ) )

(658) ( '(

(659) -z.

(660) $ ) )

(661)

(662) @ . " + " CC*UCzHX*". X". : - + # + ) : ! ) " . $ ) ) ( )

(663)

(664) . '" 9/ +" CC*UHJzHG`HJ". G". : ( }# +- ! +9 / ) . 9 # ) : )@ 0 # 0) f"

(665) ). (

(666) 8) ) ) )

(667)

(668) @ . " " CC*U&`zXH`XO". J". } /

(669)

(670) K- f ) K } } # } :+ 9 - :. 0 + / +" )) $ ) )

(671)

(672)

(673) $. @ )

(674) 8) ' '( . " ) " CC&UHCGz*O&*OJ". `". ( : : :( ) 7K ') "

(675) ( $. )

(676)

(677) @

(678) z

(679) $ $ )@ . $ )@ HC" " CC*U&`zOXX&". HC". % / # % ' + ' YY +

(680) !" 4 . )

(681)

(682) @z $ $ $ . " (" H``CUHGOz*J`*`&". HH". ) : YY 0) + +' : ! +" : . $ (

(683) -

(684) > $ $ )@ HC ) )

(685)

(686) . @ " " CCXU*Hz&H&&*". H". ) / 9 ) + + " : } !

(687) ! % " ) )

(688) - . $>- $

(689) (

(690) @ ' " " H`ÒU&CzXC*XHC". H&". ) } -

(691)

(692) +7 :$ Y ! /

(693) :%. : # +Y" /$$ $ ) )

(694)

(695) @

(696) . ;9 )@ HC< ) (

(697) " " CCGUJzHX` HX*". H*". " ? ( " 7 / + " H``Ù&*CzHHOHX". HO". Y ) : !) + 7-- jY ) " /@

(698) $ !0!

(699) f!0!

(700) . !0!

(701)

(702)

(703) '' z -. ) $

(704) f!0!

(705) @

(706) )

(707) ". ) " H``JU`GzHCG`HCJX". HX". })K ff 9'' : / }+ ! } + . Y$$ Y9 9 %"

(708) 3 0&X

(709)

(710)

(711) .

(712) ' $ )

(713) - $ > (

(714)

(715)

(716) .

(717) " + " CCUGGz*``J*``JJ". HG". - + B) Y- })

(718) + / /- "

(719) z $ . $ ) B

(720) !

(721) " CCOUHXzOOO&O".

(722)

(723) ) . ))- Y }) j -( } 7 } - + } 4 B -) Y. Y ))- - j }' j ( B % j Y }) Y ') . Y 0 ) ) 7 ( j -) Y j- j } " . $

(724)

(725) )

(726) ' ( $ " 7 ) ". H``GU&JXz``X". H`". }+ 9 %"

(727) z '(

(728) )

(729) -". ' f " CCXUXzHGCHGHH". C". #) :+ # 0 ))- Y Y-- Y ) B ) ) Y ) j }. # " ( $

(730)

(731) ; < @

(732) ) . " ' f " H``ÙH`z*XH*GH". H". % : 0K- }% Y- ! Y$- Y"

(733)

(734) z. ) $)

(735) " ' f " CCCUCz`C`G". ". 9/ jY + : : - - + /!" > . $ 7 :

(736) $ ". &". ) 7 -) Y - - Y Y(- } Y ') . Y --) 9 ))- Y " Y)

(737)

(738) z

(739) ( ) ) . @

(740) " : 7 4 " H``CUJGz`H&& `H&G". *". : 7 # "

(741) z

(742) )) ' $.

(743) ( " " H``JUOz H`&C&". O". 9/ jY + : : - - + /!" > . $ 7 :

(744) $ U CHC". X". % : #K' + 0K- }% #

(745) :+ ))- Y } 9 Y-. ! Y$- Y"

(746) >(